Scarica l'app Stockscreener
0.6751
11.24%
-0.0855
Dopo l'orario di chiusura:
.69
0.0149
+2.21%
Precedente Chiudi:
$0.7606
Aprire:
$0.77
Volume 24 ore:
249.76K
Relative Volume:
1.03
Capitalizzazione di mercato:
$41.73M
Reddito:
$9.53M
Utile/perdita netta:
$-44.61M
Rapporto P/E:
-0.7419
EPS:
-0.91
Flusso di cassa netto:
$-38.32M
1 W Prestazione:
-26.62%
1M Prestazione:
-42.30%
6M Prestazione:
-41.80%
1 anno Prestazione:
-62.07%
Intervallo 1D:
$0.6607
$0.8096
Intervallo di 1 settimana:
$0.6607
$0.944
Portata 52W:
$0.45
$2.26
Cue Biopharma Inc Stock (CUE) Company Profile
Nome
Cue Biopharma Inc
Settore
Industria
Telefono
617-949-2680
Indirizzo
40 GUEST STREET, BOSTON, MA
Confronta CUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.6751 | 41.73M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-13 | Iniziato | Jefferies | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2022-11-21 | Iniziato | Piper Sandler | Overweight |
| 2022-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-03 | Iniziato | Craig Hallum | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-04-09 | Iniziato | Stifel | Buy |
| 2020-01-28 | Iniziato | BTIG Research | Buy |
| 2020-01-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Cue Biopharma Inc Borsa (CUE) Ultime notizie
Cue Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cue Biopharma’s Strategic Focus and Financial Outlook - TipRanks
What's Going On With Cue Biopharma Shares Tuesday? - Benzinga
Cue Biopharma earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - MSN
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - The Manila Times
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Bleichroeder LP Increases Stake in Cue Biopharma Inc - GuruFocus.com
[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold
Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Wednesday - Defense World
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - Nasdaq
Cue Biopharma appoints Pasha Sarraf to board By Investing.com - Investing.com Australia
Cue Biopharma Appoints Pasha Sarraf to Board - TipRanks
Cue Biopharma appoints Pasha Sarraf to board - Investing.com
Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%What's Next? - MarketBeat
Larger animals really are more prone to cancer, debunking ‘Peto’s paradox’ - Study Finds
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) - ACCESS Newswire
Pancreatic Adenocarcinoma Market Growth Projections - openPR
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat
Artiva Biotherapeutics expands board with industry veteran - MSN
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - The Manila Times
Artiva Biotherapeutics appoints new director and committee members - MSN
Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com Nigeria
Artiva expands Board with appointment of Dan Baker, M.D - TipRanks
Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan
Geode Capital Management LLC Increases Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Geode Capital Management LLC Purchases 212,394 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) - Defense World
HPV16+ Cancer Clinical and Non-Clinical Studies, Key - openPR
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December - MarketBeat
Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World
The definitive Boston biotech layoff tracker for 2024 - The Business Journals
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India
Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com
Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat
Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com Australia
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Cue Biopharma Inc Azioni (CUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):